GRI

1.1200.00%
AA

Albert Agro

Co-Founder & Chief Medical Officer

Dr. Albert Agro, Ph.D. has been the President and Chief Executive Officer of HNZ Strategic Holdings, Inc. since September 2008. He serves as CEO and Director at Jocasta Neuroscience, Inc. He served as the Chief Executive Officer, President and Director of Sublimity Therapeutics Ltd., previously known as Sigmoid Pharma Ltd. since May 2018 until April 2021. Dr. Agro serves as Chief Medical Officer at GRI Bio, Inc. (formerly known as Glycoregimmune, Inc.) since April 2023 and served as its Senior Vice President of Clinical Development and Consultant. He is a Co-Founder of GRI Bio, Inc. (formerly known as Glycoregimmune, Inc.). He co-founded GRI Operations in 2009 and served as Chief Medical Officer of GRI Operations from August 2017 until April 2023. Dr. Agro has been Acting Chief Medical Officer of KalGene Pharmaceuticals Inc. since joining in August 2021. He served as the Chief Medical Officer of Cynapsus Therapeutics Inc. since August 2010 until October 20, 2016. He served as the Chief Medical officer of Trillium Therapeutics Inc. (Former Name: Stem Cell Therapeutics Corp.) since December 7, 2011. He served as Senior Director of Medical and Scientific Services of Axon Communications Inc. From 2003 to 2007, he was a Partner at Axon Medical Communications that helped build the Clinical Research arm of the business from 2005 to 2007, as well as Vice President, Medical and Scientific Affairs at Axon from 2003 to 2005. He is Partner at National Public Relations and co-Practice Leader in the Healthcare Group. He is an international clinical development expert in CNS diseases. Dr. Agro served as Senior Vice President of Clinical Development at TransTech Pharma, Inc., from September 2007 to December 2009. He served as Director, National Medicine, as well as Director, Immunology, Virology and Respiratory Medicine, at Boehringer Ingelheim from 2000 to 2003. In 1996, Dr. Agro joined Boehringer Ingelheim Canada Ltd as a Project Manager in Drug Development. He joined Bayer Inc. in 1998 and served as its Associate Director of Cardiopulmonary Research from 1998 to 2000. He served as a Director of Bayer Inc. and Boehringer Ingelheim. He serves as Director at Saint Elizabeth Health Care. He has been Assistant Professor, Department of Pathology and Molecular Medicine at McMaster University in Hamilton, Ontario since September 1996. He is the recipient of a Michael J. Fox Foundation Clinical Scholarship for his work on Apomorphine. He is an Undergraduate of Iowa State University, University of Guelph. Dr. Agro holds Ph.D. from Department of Medicine at McMaster University in 1995 and a post-doctoral fellowship from University of Florence in Italy. Dr. Agro has served as President and Chief Executive Officer of Columbia Therapeutics Inc. since April 2021.

Positions